|Bid||59.80 x 900|
|Ask||59.97 x 3200|
|Day's Range||59.28 - 60.05|
|52 Week Range||57.04 - 85.97|
|Beta (5Y Monthly)||0.55|
|PE Ratio (TTM)||59.61|
|Earnings Date||Feb 02, 2021 - Feb 08, 2021|
|Forward Dividend & Yield||2.72 (4.53%)|
|Ex-Dividend Date||Dec 14, 2020|
|1y Target Est||73.72|
When you think about dividend stocks, biotechs probably don't immediately come to mind. Gilead Sciences' (NASDAQ: GILD) dividend program especially stands out. The company arguably offers the best dividend of any biotech.
Gilead Sciences (NASDAQ: GILD) started the year strong. As a result, while the rest of the stock market slid, Gilead did just the opposite. To make matters worse, the World Health Organization (WHO) recently advised against using remdesivir as a treatment for COVID-19.
Daniel O'Day has made increasingly larger deals in an effort to improve the company's portfolio of cancer drugs.